Multiple Sclerosis: Payer Insight
Drug prices rising while needs remain unmet. Now payers are fighting back
Payers have had it with the high cost of Multiple Sclerosis (MS) drugs and now they’re fighting back—demanding better data to justify pricing, and using a host of strategies to offset and contain costs. Get the details in Payer Insight: Multiple Sclerosis. You’ll learn what drives treatment costs up, what payers are doing to bring them down, why assessing cost effectiveness for MS drugs is so difficult, and how payers make access and reimbursement decisions.
We interviewed 12 US and EU payers with expertise in formulary development and drug reimbursement to get their perspective on the challenges facing the MS market. Plus you’ll find out how payers view pipeline MS treatments, what advice they have for Pharma, and which clinical trials to watch.
“…it is not the insurance companies that are causing those co-pays to increase. It is the doing of the pharmaceutical industry.” - Pharmacy Director, Pharmacy Benefit Manager Order the report and you’ll receive three quarterly FirstWord Therapy Trends Update Bulletins free!
Reasons to Purchase
- Ripple effect: Rising drug costs put pressure on other needed treatments for MS patients. Do payers envision a time when patients may have to go without?
- Cost-effectiveness difficult to assess: What information are payers missing in order to measure cost-effectiveness? How will it influence PR and MA decisions?
- Route of administration: The way drugs are administered has important consequences that affect cost and adherence, and shape payers’ decisions.
- What about biosimilars and generics? Will they displace branded MS treatments, or are payers simply using them as a negotiating tool? Learn what will determine their near-term prospects.
- Needs remain unmet: Current disease modifying agents only do so much. Payers point to four main areas of unmet clinical need that affect the MS pricing landscape in different ways.
A payers’ eye view
- Cost containment: Payers are experimenting with a number of discounting, contracting, and payment schemes to contain drug costs. Which ones are showing the most promise?
- Complex PR and MA decisions: Payers predict several factors will affect pricing, reimbursement, and market access decisions in the near term. Which ones will have the greatest impact?
- Poor adherence: Patient adherence is key to assessing efficacy, but difficult to achieve. How does adherence affect drug choice, and what are payers doing to understand and improve it?
- Lack of data: With little efficacy data to support MS drugs’ high prices, payers are pushing back. What data are they demanding? How will it affect future drug launches and access decisions?
- Drugs Summary: Get a breakdown of approved and pipeline drugs, as well as payers’ thoughts about several oral, subcutaneous, and infusion therapies.
- Coverage and access recap: Learn how coverage and access decisions are made in the US and several EU countries, and what payers are doing to improve transparency. Includes an update on Obamacare for US readers.
- Clinical trials to watch: A comprehensive list of important upcoming trials for approved and pipeline products gives you a window into how the treatment landscape may evolve.
- Warnings for pharma: Payers identify the two key things providers have to do if they want to avoid past mistakes.
We interviewed 6 US payers and 6 from the EU. All interviewees have expertise in formulary development and drug reimbursement. All respondents requested that their details remain confidential.
- Pharmacy Director, Pharmacy Benefit Manager
- Chief Medical Officer, Managed Care Organisation
- Chief Medical Officer, PMT Chair, Managed Care Organisation
- Pharmacy Director, Community Health Plan
- Medical Director, Managed Care Organisation
- Pharmacy Director, Health Maintenance Organisation
- Regional Pharmaceutical and Formulary Advisor, UK
- Chief Hospital Pharmacist, Vice President Formulary Drug Committee, France
- Pharmacist Director, France
- Head of Drug Reimbursement, Germany
- Member of the Drug Commission, Germany Medical Association, Germany
- Chief Pharmacist, UK
At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed. About FirstWord
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.
- 1 Executive Summary
- 2 Research objectives
- 3 Research focus
- 4 Multiple sclerosis: overview
- 4.1 Currently approved therapies
- 4.1.1 Subcutaneous therapies
- 4.1.2 Oral therapies
- 4.1.3 Infusion drugs
- 4.2 Financial burden of multiple sclerosis
- 5 Pricing, reimbursement and market access of multiple sclerosis drugs
- 5.1 Current process of coverage and managing access to MS drugs
- 5.1.1 Coverage and access in the US
- 5.1.2 Coverage and access in the EU
- 5.1.3 Efforts to make access to MS drugs more transparent
- 5.2 Major attributes that influence pricing, reimbursement and access for MS drugs
- 6 Perspectives on future drug launches
- 6.1 Pipeline overview
- 6.2 Payer awareness and expectations of new drug launches
- 6.2.1 Expectations for once-monthly depot formulation of Copaxone
- 6.2.2 Payers require significant cost reduction for success of generics and biosimilars
- 6.3 Patient compliance and adherence to MS drugs
- 6.3.1 Role of route of administration
- 6.4 Role of post-marketing clinical trials for decisions relating to drug coverage
- 7 Methods of controlling costs
- 7.1 Strategies to offset costs
- 7.1.1 Discounting and rebating expectations
- 7.1.2 Role of biosimilars and generics in cost containment
- 7.2 Innovative solutions to contain costs of MS drugs
- 7.2.1 Preferred therapy rebates
- 7.2.2 Price protection
- 7.2.3 Portfolio contracting
- 7.2.4 Bundled payments
- 7.2.5 Outcome-based contracting
- 8 Future perspectives and how payer sentiment towards multiple sclerosis could evolve
- 8.1 Payer sentiments and challenges
- 8.1.1 Rising prices of MS drugs impact other areas of healthcare spending
- 8.1.2 Challenges in P&R and MA of MS drugs
- 8.2 Unmet clinical needs
- 8.3 Future changes to MS drug access
- 8.4 What payers will and will not pay for
- 8.5 Mistakes made and advice to pharma companies
- 8.5.1 Mistakes made and lessons learned
- 8.5.2 Advice to pharma
- 9 Appendix
- 9.1 Payers interviewed for this report
- 9.1.1 US payers
- 9.1.2 EU payers
- 9.2 Key clinical trials to watch
- 9.2.1 Approved drugs
- 9.2.2 Pipeline drugs
- 9.3 Abbreviations
- 9.4 Glossary